Thermo Fisher Scientific Inc. $TMO Shares Purchased by Findlay Park Partners LLP

Key Points

• Findlay Park Partners LLP increased its stake in Thermo Fisher Scientific by 1.3%, now owning 333,820 shares valued at approximately $166.11 million, making it 1.7% of their portfolio.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with an average price target of $593.00.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, exceeding estimates, and set guidance for Q3 2025 EPS between $5.460 and $5.510.

Findlay Park Partners LLP increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 333,820 shares of the medical research company's stock after buying an additional 4,400 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.7% of Findlay Park Partners LLP's portfolio, making the stock its 29th largest holding. Findlay Park Partners LLP owned 0.09% of Thermo Fisher Scientific worth $166,109,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the period. Port Capital LLC grew its position in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after acquiring an additional 22 shares during the period. Clark Capital Management Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after acquiring an additional 23 shares during the period. Monograph Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after acquiring an additional 23 shares during the period. Finally, Intergy Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after acquiring an additional 23 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $2.48 on Thursday, reaching $490.60. The company's stock had a trading volume of 1,407,667 shares, compared to its average volume of 2,011,074. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a market cap of $185.25 billion, a P/E ratio of 28.37, a PEG ratio of 2.61 and a beta of 0.74. The company has a 50-day simple moving average of $450.59 and a 200 day simple moving average of $455.26. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,896 shares of company stock worth $13,603,438 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TMO shares. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating on the stock. Finally, HSBC reiterated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.